Country: Canada
Language: English
Source: Health Canada
TETRACAINE (TETRACAINE HYDROCHLORIDE)
VALEO PHARMA INC
D04AB06
TETRACAINE
40MG
GEL
TETRACAINE (TETRACAINE HYDROCHLORIDE) 40MG
TOPICAL
1.5G
Ethical
ANTIPRURITICS AND LOCAL ANESTHETICS
Active ingredient group (AIG) number: 0108851002; AHFS:
APPROVED
2020-07-09
_Product Monograph _ _ _ _AMETOP GEL 4% (_Tetracaine Hydrochloride Gel)_ _ _Page 1 of 14 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION AMETOP® GEL 4% Tetracaine (as tetracaine hydrochloride) Gel, Tetracaine 4% w/w, for topical administration Topical Analgesic Valeo Pharma Inc. 16667 Hymus Blvd. Kirkland (Québec) Canada H9H 4R9 Date of Initial Authorization: JAN 17, 1997 Date of Revision: April 5, 2022 Submission Control Number: 257974 AMETOP is a registered trademark of Alliance Pharmaceuticals Limited © Alliance Pharmaceuticals Limited 2022 _Product Monograph _ _ _ _AMETOP GEL 4% (_Tetracaine Hydrochloride Gel)_ _ _Page 2 of 14 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 04/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics .................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................ 4 4 DOSAGE AND ADMINISTRATION ................................................................................ 4 4.2 Recommended Dose and Dosage Adjustment ........................................................ 4 4.4 Administration ......................................................................................................... 5 5 OVERDOS Read the complete document